Products for Research Use Only
RegisterLogin

Aliskiren

CAT: 0804-HY-12176-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12176-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia[1][2][3].
CAS Number
173334-57-1
Product Name Alternative
CGP 60536; CGP60536B; SPP 100
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Autophagy; Renin
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Aliskiren.html
Purity
99.70
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)
Smiles
COCCCOC1=CC(C[C@@H](C[C@@H]([C@H](C[C@H](C(NCC(C)(C(N)=O)C)=O)C(C)C)O)N)C(C)C)=CC=C1OC
Molecular Formula
C30H53N3O6
Molecular Weight
551.76
Precautions
H315, H319, H335
References & Citations
[1]Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754–758|[2]Buczko W, et al. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60 (5) :623-31.|[3]Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor.Biochem Biophys Res Commun, 2003, 308 (4), 698-705.|[4]Gradman AH, et al.Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005, 111 (8), 1012-1018.|[5]Chang AY, et al. Interplay between brain stem angiotensins and monocyte chemoattractant protein-1 as a novel mechanism for pressor response after ischemic stroke. Neurobiol Dis. 2014 Nov;71:292-304.|[6]Wang C, et al. Aliskiren targets multiple systems to alleviate cancer cachexia. Oncol Rep. 2016 Nov;36 (5) :3014-3022.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Clin Sci. 2025 Jan 15;139 (1) :43-53.|Department of Biological Science. National Sun Yat-Sen University. 2015 Sep.|Front Biosci (Landmark Ed) . 2023 Oct 17;28 (10) :238.|Lipids Health Dis. 2018 Jul 31;17 (1) :183. |Neurobiol Dis. 2014 Nov;71:292-304. |Department of Pharmaceutical Sciences. East Tennessee State University. 2015 May.|Drug Metab Pharmacokinet. 2024 Jun:56:101008.|Stanford University. 2025.|Toxicol Res Appl. 2018, 2:239784731880115.|Toxicol Res Appl. September 25, 2018.

Alternative Products

CatalogName
A3153-1000Aliskiren
TRC-A536040-75MG(2R)-Aliskiren (Aliskiren Impurity)
FA17280-01Aliskiren hemifumarate
259045-01Aliskiren hydrochloride
T72526-01Aliskiren fumarate
A11616-10Aliskiren 10mg

Popular Products